Ken Griffin Stealth Bio Therapeutics Corp Call Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding MITO

# of Institutions
1
Shares Held
2.94K
Call Options Held
0
Put Options Held
0
View Full List

About Stealth BioTherapeutics Corp

MITO Quotes by TradingView
  • Ticker MITO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,548,600
  • Description
  • Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duche...
More about MITO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email